ClearPoint Neuro, Inc. (CLPT) · Oct 28, 2026 · Earnings

ClearPoint Neuro earnings show 36% growth, but 2026 guidance slips

In line — EPS -$0.24 vs ~-$0.32 consensus; revenue $12.1M vs ~$12.3M consensus

ClearPoint Neuro earnings show faster growth across IRRAflow and lab services, but a lower 2026 revenue ceiling and fresh equity funding temper the read.

ClearPoint Neuro is transitioning from a neurosurgical-device company into a broader platform for IRRAflow neurocritical care, preclinical laboratory services, and eventual cell-and-gene therapy delivery. The prior quarter had already signaled that the new ClearPoint Advanced Laboratories facility should restart growth in biologics and drug delivery, while IRRAflow was driving the core product rebound.

MetricQ3 2026Q3 2025 / referenceRead
Revenue$12.1M$8.9M+36%; slightly below ~$12.3M consensus
EPS, basic and diluted-$0.24-$0.21Better than ~-$0.32 consensus
Biologics and drug delivery revenue$4.9M$4.4M+11%
Neurosurgery navigation and therapy revenue$5.4M$3.4M+59%
Capital equipment and software revenue$1.7M$1.0M+68%
Gross margin58%63%Down 5 points
Operating expenses$13.4M$10.9M+23%
2026 revenue outlook$48.0M–$50.0MPrior range: $48.0M–$52.0MTop end reduced
Cash and equivalents$46.2M$45.9M at Dec. 31, 2025Supported by $22.0M ATM proceeds

The operating rebound is real, but the revenue result was not a clean beat. Total revenue grew 36% to $12.1 million, just below the published consensus of roughly $12.3 million, while reported EPS of negative $0.24 was better than the roughly negative $0.32 expectation. That makes the quarter broadly in line rather than an unambiguous earnings win. The filing says, “Total revenue was $12.1million for the three months ended September 30, 2026,”

The mix is improving in the areas that support the longer-term platform story. Neurosurgery navigation and therapy rose 59% to $5.4 million, primarily from IRRAflow, while capital equipment and software rose 68% to $1.7 million. Biologics and drug delivery also returned to double-digit growth at $4.9 million, helped by services at ClearPoint Advanced Laboratories. This confirms the IRRAflow integration is contributing revenue and that the lab build-out is beginning to monetize, but the filing does not yet show that the higher-growth drug-delivery opportunity is scaling materially.

The main new negative is a lower ceiling on 2026 revenue. Management now guides to $48 million–$50 million, versus the $48 million–$52 million range issued in August, when it said investment was being redirected toward clinical capacity, CAL equipment, focused ultrasound, robotics, and software. The current filing states, “The Company now estimates revenue in 2026 to be between $48.0million and $50.0million.” The cut is modest and appears to reflect a deliberate investment-heavy transition, but it says the near-term commercial ramp is not accelerating as quickly as the strategic narrative.

Growth is still being bought with losses and equity. Gross margin fell to 58% from 63% as the new laboratory overhead and acquired-intangible amortization came through, while operating expenses grew 23% and nine-month operating cash use reached $20.1 million. The company raised $22.0 million through its at-the-market offering, leaving cash at $46.2 million; that extends funding capacity but increases the share count and underscores that the business is not yet self-funding.

Regulatory progress adds strategic value, but remains indirect. A partner submitted the first formal BLA for Huntington’s disease, and the company highlighted a five-year NCI-backed spinal-metastasis laser program. Those developments strengthen ClearPoint’s role as an enabling supplier, but they are not yet commercial approvals or direct revenue commitments for ClearPoint.

Bottom line: ClearPoint’s core business is recovering and the IRRAflow-plus-lab-services combination is beginning to show through, but the quarter was only broadly in line and the lower 2026 revenue ceiling keeps the story mixed. The company is advancing its platform, yet it still needs partner approvals and operating leverage to turn that strategy into durable self-funded growth.

What to watch next

Partner BLA reviews and 2027 commercial-readiness milestones

Original filing on SEC EDGAR

More ClearPoint Neuro, Inc. news

ClearPoint Neuro earnings show 36% growth, but 2026 guidance slips | CLPT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.